Altimmune (NASDAQ:ALT) Rating Reiterated by B. Riley

Altimmune (NASDAQ:ALT)‘s stock had its “buy” rating reiterated by stock analysts at B. Riley in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $20.00 price target on the stock. B. Riley’s price objective points to a potential upside of 93.61% from the company’s current price.

Several other research analysts have also recently weighed in on ALT. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Altimmune in a research report on Friday, December 1st. The Goldman Sachs Group started coverage on shares of Altimmune in a research report on Wednesday, January 24th. They set a “neutral” rating and a $13.00 price target on the stock.

Altimmune Trading Up 16.2 %

ALT traded up $1.44 on Thursday, hitting $10.33. 4,547,882 shares of the company’s stock were exchanged, compared to its average volume of 5,998,289. The firm has a 50-day moving average price of $9.92 and a 200-day moving average price of $6.69. The stock has a market cap of $555.03 million, a price-to-earnings ratio of -6.64 and a beta of 0.08. Altimmune has a fifty-two week low of $2.09 and a fifty-two week high of $14.84.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Altimmune by 6.8% in the fourth quarter. Vanguard Group Inc. now owns 3,571,972 shares of the company’s stock valued at $40,185,000 after buying an additional 227,677 shares during the last quarter. Gerber LLC purchased a new stake in Altimmune during the fourth quarter worth about $2,878,000. American International Group Inc. increased its stake in Altimmune by 6.5% during the fourth quarter. American International Group Inc. now owns 26,268 shares of the company’s stock worth $296,000 after purchasing an additional 1,599 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Altimmune by 33.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,417 shares of the company’s stock worth $151,000 after purchasing an additional 3,370 shares during the period. Finally, Occudo Quantitative Strategies LP purchased a new stake in Altimmune during the fourth quarter worth about $304,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.